Effect of Cancer Stage on Adverse Kidney Outcomes in Patients Receiving Immune Checkpoint Inhibitors for Melanoma-Reference-Cited by-同舟云学术

Effect of Cancer Stage on Adverse Kidney Outcomes in Patients Receiving Immune Checkpoint Inhibitors for Melanoma

Published:2022-11 Issue:11 Volume:7 Page:2517-2521
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Wang Qiyu,Strohbehn Ian A.,Zhao Sophia,Seethapathy Harish,Strohbehn Samuel D.,Hanna Paul,Lee Meghan,Fadden Riley,Sullivan Ryan J.,Boland Genevieve M.,Reynolds Kerry L.,Sise Meghan E.

Funder

Merck

National Institutes of Health

Publisher

Elsevier BV

Subject

Nephrology

Reference8 articles.

1. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

2. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors;Seethapathy;Clin J Am Soc Nephrol,2019

3. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors;Cortazar;Kidney Int,2016

4. Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort;Stein;Nephrol Dial Transplant,2021

5. Risk of percutaneous renal biopsy of native kidneys in the evaluation of acute kidney injury;Korbet;Clin Kidney J,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor‐induced kidney disease;Immunological Reviews;2023-07-21

2. Multiple drugs;Reactions Weekly;2023-03-04